Cavtat-Dubrovnik, Croatia
More info
Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201.
IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.
Innate Pharma SA announces a turnover of 5.9 million euros for the first nine months of 2008, compared with 5.1 million euros for the same period in 2007.
Innate Pharma SA announces that the preclinical rationale of the gamma-delta T cell immunotherapy in type-C viral hepatitis was presented today at the AASLD (American Association for the Study of Liver Diseases) Annual Meeting in San Francisco, USA.
Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH 2101 from Novo Nordisk A/S in the context of a swap of products.
Innate Pharma SA announces its financial results for the first half of 2008. Results for the first half of 2008 show a stable operational loss (4.7 million euros for the six-month period ended June 30, 2008 vs. 4.9 million euros in the same period last year) and a controlled consumption of cash from the operations (5.9 million euros for the six-month period ended June 30, 2008 vs. 4.5 million euros in the same period last year).
Innate Pharma SA announces 4.4 million Euros in turnover for the first semester of 2008.
Cash, cash equivalents and current financial instruments at the end of June 2008 amounted to 43.0 million euros. The Company updates on the acquisition of its new corporate headquarters during the second quarter of 2008.